+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 127 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589924
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Cough - Drugs In Development, 2022, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Cough - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 2, 9, 6, 1, 13, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageCough - Overview
Cough - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Cough - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Cough - Companies Involved in Therapeutics DevelopmentCough - Drug ProfilesCough - Dormant ProjectsCough - Discontinued ProductsCough - Product Development Milestones
Featured News & Press Releases
  • Mar 29, 2022: Aldeyra Therapeutics to announce top-line data for systemic RASP modulator ADX-629 at 2022 Research & Development Day
  • Mar 22, 2022: Trevi Therapeutics hosting key opinion leader webinar on the seriousness of chronic cough in Idiopathic Pulmonary Fibrosis (IPF)
  • Mar 16, 2022: Trevi ends enrolment early in Phase II IPF chronic cough trial after positive interim data
  • Feb 24, 2022: Trevi Therapeutics reports statistically significant result on interim analysis from the Ph2 CANAL trial of Nalbuphine ER in the treatment of chronic cough in idiopathic pulmonary fibrosis
  • Feb 04, 2022: Algernon Pharmaceuticals announces completion of enrollment in its Phase 2 study of Ifenprodil for IPF and chronic cough
  • Jan 24, 2022: Merck provides U.S. and Japan regulatory update for Gefapixant
  • Jan 20, 2022: MSD obtained manufacturing and marketing approval for Rifunua tablets, the world's first selective P2X3 receptor antagonist for chronic cough.
  • Jan 17, 2022: Algernon receives positive FDA feedback on Phase IIb chronic cough trial
  • Dec 28, 2021: Hansoh Pharmaceutical Group Company announces clinical trial notice of HS-10383 tablets
  • Dec 21, 2021: Sino Biopharmaceutical : Innovative medicine “TCR1672” obtained approval for clinical trial
  • Dec 13, 2021: BELLUS Health announces positive topline results from its phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough
  • Dec 02, 2021: Algernon Pharmaceuticals projects full enrollment for phase 2 IPF and chronic cough trial
  • Nov 01, 2021: BELLUS Health convenes virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist BLU-5937
  • Oct 21, 2021: Axalbion treats first subjects in phase II chronic cough treatment trial
  • Oct 08, 2021: Sino Biopharmaceutical announces IND application of innovative medicine “TCR1672” filed with and accepted by FDA
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Cough, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Cough - Pipeline by Adare Pharma Solutions, 2022
  • Cough - Pipeline by AfaSci Inc, 2022
  • Cough - Pipeline by Aldeyra Therapeutics Inc, 2022
  • Cough - Pipeline by Algernon Pharmaceuticals Inc, 2022
  • Cough - Pipeline by Antheia Inc, 2022
  • Cough - Pipeline by Asana BioSciences LLC, 2022
  • Cough - Pipeline by Axalbion SA, 2022
  • Cough - Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2022
  • Cough - Pipeline by BELLUS Health Inc, 2022
  • Cough - Pipeline by Charleston Laboratories Inc, 2022
  • Cough - Pipeline by Chiesi Farmaceutici SpA, 2022
  • Cough - Pipeline by Conrig Pharma ApS, 2022
  • Cough - Pipeline by Evotec SE, 2022
  • Cough - Pipeline by Future Analgesics, 2022
  • Cough - Pipeline by Grunenthal GmbH, 2022
  • Cough - Pipeline by Hyundai Pharma Co Ltd, 2022
  • Cough - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
  • Cough - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
  • Cough - Pipeline by Korea United Pharm Inc, 2022
  • Cough - Pipeline by Merck & Co Inc, 2022
  • Cough - Pipeline by NeRRe Therapeutics Ltd, 2022
  • Cough - Pipeline by Nippon Chemiphar Co Ltd, 2022
  • Cough - Pipeline by Nocion Therapeutics Inc, 2022
  • Cough - Pipeline by Nuformix Plc, 2022
  • Cough - Pipeline by PhytoHealth Corp, 2022
  • Cough - Pipeline by Shionogi & Co Ltd, 2022
  • Cough - Pipeline by Sino Biopharmaceutical Ltd, 2022
  • Cough - Pipeline by SiteOne Therapeutics Inc, 2022
  • Cough - Pipeline by SolAeroMed Inc, 2022
  • Cough - Pipeline by Trevi Therapeutics Inc, 2022
  • Cough - Pipeline by Tris Pharma Inc, 2022
  • Cough - Pipeline by Whan In Pharm Co Ltd, 2022
  • Cough - Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022
  • Cough - Dormant Projects, 2022
  • Cough - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Cough, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Adare Pharma Solutions
  • AfaSci Inc
  • Aldeyra Therapeutics Inc
  • Algernon Pharmaceuticals Inc
  • Antheia Inc
  • Asana BioSciences LLC
  • Axalbion SA
  • Beijing Tide Pharmaceutical Co Ltd
  • BELLUS Health Inc
  • Charleston Laboratories Inc
  • Chiesi Farmaceutici SpA
  • Conrig Pharma ApS
  • Evotec SE
  • Future Analgesics
  • Grunenthal GmbH
  • Hyundai Pharma Co Ltd
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Korea United Pharm Inc
  • Merck & Co Inc
  • NeRRe Therapeutics Ltd
  • Nippon Chemiphar Co Ltd
  • Nocion Therapeutics Inc
  • Nuformix Plc
  • PhytoHealth Corp
  • Shionogi & Co Ltd
  • Sino Biopharmaceutical Ltd
  • SiteOne Therapeutics Inc
  • SolAeroMed Inc
  • Trevi Therapeutics Inc
  • Tris Pharma Inc
  • Whan In Pharm Co Ltd
  • Wuhan LL Science and Technology Development Co Ltd